{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T11:27:49Z","timestamp":1790681269592,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T00:00:00Z","timestamp":1599696000000},"content-version":"vor","delay-in-days":1379,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["jlr.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Lipid Research"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1194\/jlr.p071704","type":"journal-article","created":{"date-parts":[[2016,10,6]],"date-time":"2016-10-06T02:58:16Z","timestamp":1475722696000},"page":"2217-2224","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Effect of evolocumab on cholesterol synthesis and absorption"],"prefix":"10.1016","volume":"57","author":[{"given":"Matthew","family":"Peach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Fitzpatrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Hamilton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ransi","family":"Somaratne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott M.","family":"Wasserman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Stephen","family":"Djedjos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1194\/jlr.P071704_bib1","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet."},{"key":"10.1194\/jlr.P071704_bib2","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1194\/jlr.P071704_bib3","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0021-9150(03)00248-X","article-title":"Approaches to measuring cholesterol absorption in humans","volume":"174","author":"Matthan","year":"2004","journal-title":"Atherosclerosis."},{"key":"10.1194\/jlr.P071704_bib4","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1194\/jlr.P900039-JLR200","article-title":"Alterations in cholesterol absorption\/synthesis markers characterize Framingham offspring study participants with CHD","volume":"50","author":"Matthan","year":"2009","journal-title":"J. Lipid Res."},{"key":"10.1194\/jlr.P071704_bib5","doi-asserted-by":"crossref","first-page":"6429","DOI":"10.3748\/wjg.v12.i40.6429","article-title":"Emerging roles of the intestine in control of cholesterol metabolism","volume":"12","author":"Kruit","year":"2006","journal-title":"World J. Gastroenterol."},{"key":"10.1194\/jlr.P071704_bib6","doi-asserted-by":"crossref","first-page":"S120","DOI":"10.1194\/jlr.R800026-JLR200","article-title":"Fifty years of advances in bile acid synthesis and metabolism","volume":"50","author":"Russell","year":"2009","journal-title":"J. Lipid Res."},{"key":"10.1194\/jlr.P071704_bib7","first-page":"300","article-title":"Detection of changes in human cholesterol metabolism","volume":"2","author":"Miettinen","year":"1970","journal-title":"Ann. Clin. Res."},{"key":"10.1194\/jlr.P071704_bib8","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1093\/oxfordjournals.aje.a115479","article-title":"Serum plant sterols and cholesterol precursors reflect cholesterol absorption and synthesis in volunteers of a randomly selected male population","volume":"131","author":"Miettinen","year":"1990","journal-title":"Am. J. Epidemiol."},{"key":"10.1194\/jlr.P071704_bib9","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1093\/ajcn\/43.1.92","article-title":"Serum plant sterols and their relation to cholesterol absorption","volume":"43","author":"Tilvis","year":"1986","journal-title":"Am. J. Clin. Nutr."},{"key":"10.1194\/jlr.P071704_bib10","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1161\/01.ATV.20.5.1340","article-title":"Noncholesterol sterols and cholesterol lowering by long-term simvastatin treatment in coronary patients: relation to basal serum cholestanol","volume":"20","author":"Miettinen","year":"2000","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1194\/jlr.P071704_bib11","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0021-9150(02)00054-0","article-title":"Ineffective decrease of serum cholesterol by simvastatin in a subgroup of hypercholesterolemic coronary patients","volume":"164","author":"Miettinen","year":"2002","journal-title":"Atherosclerosis."},{"key":"10.1194\/jlr.P071704_bib12","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1194\/jlr.P800042-JLR200","article-title":"Comparison of the effects of maximal dose atorvastatin and rosuvastatin therapy on cholesterol synthesis and absorption markers","volume":"50","author":"van Himbergen","year":"2009","journal-title":"J. Lipid Res."},{"key":"10.1194\/jlr.P071704_bib13","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1046\/j.1365-2362.2003.01229.x","article-title":"Synthesis and absorption markers of cholesterol in serum and lipoproteins during a large dose of statin treatment","volume":"33","author":"Miettinen","year":"2003","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1194\/jlr.P071704_bib14","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1194\/jlr.M900032-JLR200","article-title":"Cholesterol absorption and synthesis markers in individuals with and without a CHD event during pravastatin therapy: insights from the PROSPER trial","volume":"51","author":"Matthan","year":"2010","journal-title":"J. Lipid Res."},{"key":"10.1194\/jlr.P071704_bib15","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1210\/jc.2009-1952","article-title":"Indices of cholesterol metabolism and relative responsiveness to ezetimibe and simvastatin","volume":"95","author":"Lakoski","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1194\/jlr.P071704_bib16","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1185\/030079908X253663","article-title":"Effects of ezetimibe, simvastatin, atorvastatin, and ezetimibe-statin therapies on non-cholesterol sterols in patients with primary hypercholesterolemia","volume":"24","author":"Assmann","year":"2008","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1194\/jlr.P071704_bib17","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1194\/jlr.M001487","article-title":"Baseline cholesterol absorption and the response to ezetimibe\/simvastatin therapy: a post-hoc analysis of the ENHANCE trial","volume":"51","author":"Jakulj","year":"2010","journal-title":"J. Lipid Res."},{"key":"10.1194\/jlr.P071704_bib18","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.atherosclerosis.2012.09.001","article-title":"Effects of ezetimibe added to statin therapy on markers of cholesterol absorption and synthesis and LDL-C lowering in hyperlipidemic patients","volume":"225","author":"Thongtang","year":"2012","journal-title":"Atherosclerosis."},{"key":"10.1194\/jlr.P071704_bib19","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1161\/01.CIR.0000034044.95911.DC","article-title":"Inhibition of intestinal cholesterol absorption by ezetimibe in humans","volume":"106","author":"Sudhop","year":"2002","journal-title":"Circulation."},{"key":"10.1194\/jlr.P071704_bib20","first-page":"1000139","article-title":"Assessment of cholesterol absorption and synthesis in Japanese patients with type-2 diabetes and lipid-lowering effect of ezetimibe","volume":"2","author":"T.","year":"2011","journal-title":"J. Diabetes Metab."},{"key":"10.1194\/jlr.P071704_bib21","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.atherosclerosis.2011.06.010","article-title":"Where does the interplay between cholesterol absorption and synthesis in the context of statin and\/or ezetimibe treatment stand today?","volume":"217","author":"Descamps","year":"2011","journal-title":"Atherosclerosis."},{"key":"10.1194\/jlr.P071704_bib22","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1161\/01.ATV.0000134621.14315.43","article-title":"Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia","volume":"24","author":"Dubuc","year":"2004","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1194\/jlr.P071704_bib23","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.113.006720","article-title":"Proprotein convertase subtilisin kexin type 9 promotes intestinal overproduction of triglyceride-rich apolipoprotein B lipoproteins through both low-density lipoprotein receptor-dependent and -independent mechanisms","volume":"130","author":"Rashid","year":"2014","journal-title":"Circulation."},{"key":"10.1194\/jlr.P071704_bib24","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/00041433-199706000-00003","article-title":"3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and hepatic apolipoprotein B secretion","volume":"8","author":"Huff","year":"1997","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1194\/jlr.P071704_bib25","doi-asserted-by":"crossref","first-page":"9820","DOI":"10.1073\/pnas.0903849106","article-title":"A proprotein convertase subtilisin\/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates","volume":"106","author":"Chan","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"10.1194\/jlr.P071704_bib26","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(14)61374-X","article-title":"Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet."},{"key":"10.1194\/jlr.P071704_bib27","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1316222","article-title":"A 52-week placebo-controlled trial of evolocumab in hyperlipidemia","volume":"370","author":"Blom","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1194\/jlr.P071704_bib28","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1001\/jama.2014.4030","article-title":"Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial","volume":"311","author":"Robinson","year":"2014","journal-title":"JAMA."},{"key":"10.1194\/jlr.P071704_bib29","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1016\/j.jacc.2014.03.019","article-title":"Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab","volume":"63","author":"Stroes","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1194\/jlr.P071704_bib30","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(14)61399-4","article-title":"PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet."},{"key":"10.1194\/jlr.P071704_bib31","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1016\/j.jacc.2014.03.018","article-title":"Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab","volume":"63","author":"Koren","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1194\/jlr.P071704_bib32","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1016\/j.jacc.2012.08.986","article-title":"Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins","volume":"60","author":"Dias","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1194\/jlr.P071704_bib33","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1016\/S0140-6736(12)61771-1","article-title":"Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study","volume":"380","author":"Koren","year":"2012","journal-title":"Lancet."}],"container-title":["Journal of Lipid Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002222752034548X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002222752034548X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1194\/jlr.P071704","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T23:11:09Z","timestamp":1640041869000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002222752034548X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":33,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["S002222752034548X"],"URL":"https:\/\/doi.org\/10.1194\/jlr.p071704","relation":{},"ISSN":["0022-2275"],"issn-type":[{"value":"0022-2275","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of evolocumab on cholesterol synthesis and absorption","name":"articletitle","label":"Article Title"},{"value":"Journal of Lipid Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1194\/jlr.P071704","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 ASBMB. Currently published by Elsevier Inc; originally published by American Society for Biochemistry and Molecular Biology.","name":"copyright","label":"Copyright"}]}}